

**Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory Committee**

Food and Drug Administration  
Center for Drug Evaluation and Research  
Hilton, The Ballrooms, 620 Perry Parkway, Gaithersburg, MD.

*Clinical Risk Management of HPA Axis Suppression in Children  
with Atopic Dermatitis being treated with Topical Corticosteroids*

**Bibliography**

The Harriet Lane Handbook, 15<sup>th</sup> Edition, Topical Steroid Potency Ranking, page 908-909.

Memorandum: ODS Postmarketing Safety Review (PID0303434), Marilyn R. Pitts,  
September 24, 2003

Memorandum: ODS Postmarketing Safety Review (PID# D030433), Renan A. Bonnel,  
September 24, 2003

Leung, D., and Bieber, T., Seminar: Atopic Dermatitis, The Lancet, 2003, 361, 151-160.

Drake LA., et al, Guidelines of care for the use of topical glucocorticosteroids, American  
Academy of Dermatology, Inc., 1996, 35, 615-619.

Helfer, EL., and Rose, LI., Corticosteroids and Adrenal Suppression, Characterizing and  
Avoiding the Problem, Drugs, 1989, 38 (5): 838-845.

Grinspoon, SD., and Biller, BM., Clinical Review 62, Laboratory Assessment of Adrenal  
Insufficiency, Journal of Clinical Endocrinology and Metabolism, 1994, 79 (4) 923- 931.